Proteases are one of the most abundant classes of enzymes and are involved in a wide range of biological processes, including cell-cycle progression, cell signaling, proliferation and death, protein trafficking and immune response. Proteases are also involved in many human diseases, ranging from degenerative and inflammatory diseases to infectious diseases. Therefore, proteases are often targeted by the pharmaceutical industry, and protease inhibitor drugs are currently in use for treatment of coagulation disorders, hypertension, HIV infection, cancer and diabetes 1 .
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Proteases bind their substrates through hydrogen bond interactions with the substrate peptide backbone and by hydrophobic and electrostatic contacts between the substrate side chains and well-defined pockets within the active site (Fig. 1a) . There are seven distinct classes of proteases (aspartate, cysteine, glutamate, metalloproteases, serine, threonine and the newly identified asparagine peptide lyases 2 ), grouped according to the amino acid or ion that catalyzes peptide bond cleavage (Fig. 1b-f) , and the mechanism of substrate cleavage determines which type of chemical entity can be used to inhibit each protease family 3 . For cysteine, serine and threonine proteases, an electrophilic group can covalently modify the catalytic residue in a reversible or irreversible manner. In the case of metalloproteases, functional groups that coordinate the catalytic metal can achieve potent inhibition. For all protease families, potent transition state analogs can be designed that are based on structural and enzymatic studies.
Although recent advances in high-throughput screening (HTS) technologies, structural biology, computational modeling and combinatorial chemistry have enabled the design of potent protease inhibitors 1, 4, 5 , developing protease inhibitors as drugs has remained a challenge, and achieving target specificity has been the main hurdle to overcome. This is because the reaction mechanism is highly conserved among each protease class and because proteases often have many closely related family members, resulting in lead compounds that often inhibit more than one target, potentially causing unwanted side effects. Unfortunately, the traditional approach of hitto-lead optimization takes into account in vivo off-target effects fairly late in the process (Fig. 2a) . Although advances in structural biology have revolutionized inhibitor design, it is necessary to broaden the platform of inhibitor development to allow for direct screening of compounds in cells and in vivo. This approach focuses development on compounds that show minimal side effects and that inhibit the target protease in a biologically relevant context (Fig. 2b) .
There have been a number of success stories in the development of drugs that target proteases 1, 5 ; however, here we highlight what we believe to be the two main challenges in the development of protease inhibitors as drugs: (i) validating proteases as drug targets, including obtaining a clear understanding of their biological functions, and (ii) designing specific inhibitors despite the large number of proteases found in a given organism. We also present recent technological advances that we believe will help address these challenges, emphasizing the use of activity-based probes (ABPs) as tools to understand the biological role of proteases and to measure off-target effects and on-target inhibition in vitro and in vivo. Finally, we describe recent advances in screening technologies for intact cells and living animals, as well as recently developed proteomic approaches for the identification of protease substrates.
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The majority of proteases are translated as zymogens that need to be activated, usually through proteolysis or conformational alteration. This activation event is spatially and temporally controlled by distinct mechanisms. For example, cysteine cathepsins are processed in a pH-dependent manner when they reach the lysosome 8 , and other proteases, such as the cysteine protease domain (CPD) of the multifunctional autoprocessing repeats toxin (MARTX) found in Vibrio cholera 9 , which autoprocesses in response to inositol hexakisphosphate (Ins 6 P) binding, have evolved allosteric mechanisms of activation. Alternatively, protease activation can be regulated through the formation of large protein complexes (for example, through activation of caspase-1 upon formation of the inflamasome complex 10 , or through formation of receptor-triggered complexes, as exemplified by initiator caspase activation 11 ) or by self-compartmentalization of their proteolytic subunits such as with the proteasome.
Proteases have multiple biological functions, often interacting with major signaling pathways 12, 13 . These functions can be controlled by changes in localization of the protease or substrate in response to different stimuli. For example, substrates are targeted for degradation by the proteasome through polyubiquitination, and their access to the proteolytic cavity is regulated in an ATPdependent manner 14 . Cathepsins are a particularly complex example of this; in the lysosome, degradation of the substrates of cathepsins is controlled by trafficking substrates into this organelle. By contrast, they have also been shown to regulate innate and adaptive immunity and tumor progression, depending on their localization 8 . Release of cathepsin B into the cytosol activates caspase 8 and triggers apoptosis 8 . Export of cathepsins to the tumor microenvironment results in extracellular matrix (ECM) degradation 8, 15 . Trafficking of cathepsin C in NK cell and T lymphocyte granules results in the activation of serine proteases involved in the innate immune response and inflammation 8 .
This complexity of regulation and effects makes successful targeting of proteases extremely challenging, as was poignantly illustrated by the clinical inhibition of MMPs in cancer. Targeted for their involvement in ECM degradation during angiogenesis and metastasis, MMPs are also involved in maintaining homeostasis of the extracellular environment, as well as in regulating cell signaling and innate immunity. Inhibition of some MMPs has actually been shown to promote tumor growth. This duality of function, coupled with the difficulty in designing specific inhibitors, has caused many MMP inhibitors in clinical trials to fail 16 . In complex multifactorial diseases such as cancer, it is essential to know which specific protease is important in each disease subpopulation. This is particularly evident with cysteine cathepsins; although increased levels of cathepsins B and L activities correlate with tumor malignancy, an increase in cathepsins H and S activities can result in either a better or a worse prognosis, depending on the type of cancer 15 .
In some biological pathways, multiple proteases work together to achieve a common goal, such as ECM degradation during metastasis or hemoglobin degradation in Plasmodium species. Most proteases involved in the initial stages of hemoglobin degradation (falcipains and plasmepsins) have redundant roles, as demonstrated by the viability of parasites in which these proteases have been knocked out 17 . However, proteases involved at the later stages of degradation, such as dipeptidyl aminopeptidase 1 (DPAP1) 18, 19 and several other aminopeptidases 20 , In the case of zinc metalloproteases (e), aspartate proteases (f) and glutamate proteases (not depicted), a carboxylic acid group or metal ion activates a water molecule, leading to acid-base catalysis. The seventh and newest protease family, the asparagine peptide lyases, cleave themselves using an asparagine residue as the nucleophile 2 (not depicted).
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New tools to study protease function
Given the need to further understand the complex roles of proteases, several techniques have been developed and enhanced to identify protease targets, locations and modes of regulation. These include ABPs as well as proteomics-based approaches.
Activity-based probes. Activity-based probes are small-molecule reporters designed to be highly selective for the catalytically active form of a protease or protease family (Fig. 3b) , allowing assessment of protease activity within living cells or in whole organisms [21] [22] [23] [24] [25] . Most ABPs consist of three parts: a warhead, a spacer and/or recognition element and a tag (Fig. 3b) . They are also inhibitors of the target protease, allowing them to be used with better temporal control than conditional gene disruption or RNA-mediated interference (RNAi) methods. For these reasons, ABPs have begun to find applications in early stage drug discovery 18, [26] [27] [28] [29] [30] [31] [32] . For example, biotin versions of eponemycin and epoxomycin identified the proteasome as the target of these natural antitumor products 18, [26] [27] [28] [29] [30] [31] [32] . This emphasis on early stage drug discovery has led to the clinical development of epoxyketone inhibitors such as carfilzomib as proteasome-specific drugs 33 . As most ABPs irreversibly modify the enzyme active site, libraries of covalent inhibitors can be used in forward chemical genetics screens to identify compounds that induce a specific phenotype. Hits are then converted into ABPs to isolate targeted enzymes for identification by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (Fig. 4a) . This approach has successfully identified proteases involved in malaria parasite Plasmodium falciparum egress from infected red blood cells (RBCs) 28 , and it has also identified proteins involved in Toxoplasma gondii invasion 34 . ABPs are especially useful in biological systems that are not amenable to genetic manipulation or regulation by RNAi. For example, an ABP has been used to demonstrate that P. falciparum activates the RBC calpain during egress 35 . There are other examples where ABPs were found to be essential for the identification and localization of the active forms of the proteases. One is a study that identified infiltrating macrophages as the cells that express and activate cysteine cathepsins at the tumor invasive front in response to IL-4 secreted by cancer cells 36 . Another study followed the kinetics of caspases activation during apoptosis 37 .
A further use of ABPs in vivo has been to determine the extent of target inhibition needed to observe beneficial downstream effects. ABPs were used to show that complete and prolonged inhibition of cathepsin C is required to decrease the level of activity of downstream serine proteases involved in inflammation 38 . Similarly, because DPAP1 is highly expressed in P. falciparum, ABPs revealed that its activity needs to be inhibited for at least 3 h in order to kill the parasite 18 .
Perhaps one of the most powerful applications for ABPs is their use to visualize protease activity using modern imaging modalities. Because ABPs covalently bind only to active protease targets, it is possible to monitor, in a single experiment, not only activation but also localization, distribution and biochemical activity of proteases in cells and in vivo (Fig. 4b) . This has been shown in multiple mouse models of cancer, using cysteine cathepsin probes to noninvasively detect cathepsin activity in tumors 11, 39, 40 . Additionally, ABPs can be used to monitor the efficacy of drug treatment in vivo 39 or to measure protease activation in response to a drug 11, 40 .
Although ABPs are valuable tools to study proteases, it is difficult to make probes that are selective for only one member of a protease family, but a few success stories have emerged. In a recent study, an ABP that selectively inhibited and labeled the hepatitis C virus NS2/3 protease was designed by taking advantage of a cysteine residue that is relatively close to the active site 41 . An electrophilic group that reacts with the cysteine residue was added to a reversible inhibitor of NS2/3, creating a covalent linkage between the inhibitor and the enzyme, which improved potency and selectivity. This approach may also be broadly applicable to the study of proteases, using engineered point mutations that render the target protease sensitive to ABP binding, similarly to recent methods for selective targeting and inhibition of kinases 42 .
Proteomics-based substrate identification. Although linking proteases to their substrates is essential to understand their functions, it is notoriously difficult to identify protease substrates because the end products of the reaction must be identified among the pool of cellular proteins. Furthermore, the resultant peptide fragments provide little information regarding the protease that produced them. A number of proteomic approaches have recently been developed that allow specific enrichment of the newly generated peptide fragments resulting from proteolysis, within a biologically relevant context (Supplementary Box 1) [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] .These methods have been used to map proteolytic events during processes such as apoptosis 48, 50 , inflammation 43 or rupture of malaria-infected RBCs 45 . Figure 2 Schematic presentation of the hit-tolead process. (a) In a classical protease drug discovery approach, the emphasis of screening and optimization is on maximizing the potency of a hit compound for a recombinant protease. Off-target effects and efficacy are usually tested after the optimization process, and problems encountered when testing the compounds in cultures and in vivo require either modifying the structure of the lead inhibitor to solve a particular issue or selecting a different chemotype for further optimization. (b) In this review, we propose a holistic approach, in which the emphasis is on identifying hits in a more complex and relevant context (intact cells), incorporating the specificity profile of hits to identify and optimize lead compounds. We believe that placing the emphasis of the hit-to-lead optimization process on selectivity instead of just on potency will help prevent off-target effects and thus increase the chances for developing protease inhibitor drugs with minimum side effects.
Problems:
Off-target effects 
In addition, new approaches to selectively activate a protease-mediated biological process have been devised. In one such example, the proenzyme cleavage site of several apoptotic caspases was converted into a tobacco etch virus (TEV) cleavage sequence, allowing them to be activated by a small molecule-regulated TEV protease. This conferred temporal control of caspase activity in the cell, allowing identification of distinct caspase substrates during apoptosis 56 . As many proteases require proteolytic cleavage to be activated, this method could be broadly applied. Combining the use of ABPs with proteomic approaches to identify natural substrates should help determine the biological function of proteases.
Challenges for in vitro development of protease inhibitors
The design of small-molecule inhibitors is often challenging because the chemistry of peptide bond cleavage overlaps within protease classes, and proteases belonging to the same subfamily generally have similar substrate and inhibitor specificities (Fig. 1) . Consequently, structural biologists have focused on finding alternate ways to inhibit proteases, such as blocking allosteric sites and exosites 1 . Recent studies suggest that some proteases cleave their substrates through an induced-fit mechanism 57, 58 , which could be targeted by inhibitors that stabilize the inactive conformation. Alternatively, as seen with caspases, molecules can be designed to lock an enzyme in its zymogen conformation 59, 60 . Finally, it may also be possible to inhibit a protease by targeting the acyl-enzyme intermediate if its hydrolysis is the rate-limiting step in the catalytic process 61 .
Another obstacle to designing small-molecule inhibitors is that the conditions in which inhibitors are tested in vitro, using recombinant or purified enzymes, are different from the enzyme's environment in vivo. This discrepancy has been demonstrated for kinases, where the effect of inhibitors in cell-based assays correlated better with IC 50 values determined in lysates than with IC 50 values determined with recombinant enzymes 62 . There are multiple reasons why in vitro testing with purified targets may provide only limited information on leads. First, specific binding of the inhibitor to off-target proteases, or other nonspecific associations, might reduce the effective concentration of an inhibitor in the cell. Second, pH, salt concentration, viscosity and protein concentrations can affect enzyme activity, specificity and stability, so assay conditions in vitro might not reflect those in vivo. Third, proteins are dynamic macromolecules that adopt a range of different conformations, and interactions with small molecules and other proteins can change the distribution of these conformations. For example, the CPD domain of the MARTX toxin was initially reported to be allosterically activated by GTP 63 , but recent work has shown that InsP 6 is the biologically relevant activator 9, 64 , and the CPD domain of Clostridium difficile shows some activity even in the absence of InsP 6 (ref. 65) . Therefore, prior to the identification of the activator, IC 50 values of CPD inhibitors would have been markedly underestimated. Finally, in vitro systems fail to take into account such issues as delivery, partitioning, cell permeability and cell stability. For example, probes and inhibitors that are highly specific for a cytosolic target in vitro often show cross-reactivity with lysosomal proteases when tested in cells, owing to accumulation as a result of endocytosis. 11, 66 .
New approaches to define inhibitor specificity in vivo
Given the challenges associated with developing potent and specific inhibitors using in vitro techniques, an alternative may be to focus on cellular and in vivo approaches that bypass some of the difficulties associated with in vitro screening while still leading to potent inhibitors.
Screening protease inhibitors in a biological context. Carrying out assays in living cells has the potential to provide a more accurate determination of inhibitor potency, efficacy and specificity. One approach is to design a reporter substrate that is primarily cleaved by the target protease in a complex cellular extract or even in intact cells. Although it is typically very difficult to make substrates with absolute specificity for a given protease, ABPs can be used to screen for selective substrates by correlating target labeling with inhibition of substrate turnover. This method was recently used to identify the (Pro-Arg) 2 Rho fluorescent substrate as selective for DPAP1 in P. falciparum lysates and for cathepsin C in rat liver extract 18, 67 . This substrate can also be used for HTS, avoiding the need to purify or express these proteases. Using cell-permeable ABPs, correlating target labeling with inhibition of substrate turnover can also identify selective reporter substrates in intact cells, as seen with the cellpermeable substrate Gly-Phe-AFC, which was not cleaved in cell lines or in bone marrow lysates lacking cathepsin C 68 .
Carrying out assays in lysates or in intact cells also allows for concurrent measurement of multiple protease activities. One example is the recent development of two specific, differently labeled fluorogenic substrates that can report chymotrypsin-like and caspase-like proteasomal activities simultaneously 69 . Because of the recent advances in methods to map substrate specificity of proteases 70 , we believe that substrates designed to be used will become increasingly widespread.
Finally, display methods can be used to screen large libraries of peptides to identify selective substrates in vivo. In a recent example, a phage-display peptide library was repeatedly injected, amplified and reinjected into mice with mammary tumors, allowing the reporters that use the active protease's own chemistry to distinguish it from its zymogen or inhibited form. Most ABPs consist of three parts: a warhead (an electrophilic moiety that reacts with the active site nucleophile to result in a covalent and irreversible adduct), a spacer and/or recognition element that targets the probe to a specific target protease and a tag (usually a fluorescent dye and/or an affinity handle, like biotin).
r e V i e W identification of sequences that were used to make fluorogenic substrates for noninvasive imaging of cancer 71 . Although the tumor proteases responsible for cleaving these substrates were not identified, such tumor-specific reporters of proteolysis could also be used to screen for new inhibitors in vivo. Although cell-based screening methods, when coupled with effective tools for monitoring target inhibition, have the potential to be a useful way to identify lead compounds, it should be noted that compounds that alter expression levels of protease targets could also appear to be active site-directed inhibitors. However, such occurrences might provide valuable information, and these compounds could be separated from the true active site inhibitors by using counter screening assays or by using western blots to assess protease levels.
Design of nonpeptidic inhibitors.
One approach used to generate specific protease inhibitors and substrates is to move away from the natural peptide scaffold by incorporating non-natural amino acids.
This has been extensively done with cysteine proteases 18, 28, [72] [73] [74] [75] . Although peptidic inhibitors generally have poor pharmacological properties, the structure of a protease bound to a peptidic inhibitor has often served as the initial template for structure-based design of nonpeptidic inhibitors and transition-state analogs 1, 5 . Nonpeptidic scaffolds for protease inhibitors are usually identified through screening methods such as HTS of small drug-like molecules 1, 5 , in silico screening or fragment-based screening 4 . Once such a scaffold has been successfully identified, a combination of structural, computational and structure-activity relationship (SAR) methods can be used to optimize initial hits into potent drug leads 1, 4, 5 .
Alternatively, substrate-activity screening (SAS) 76, 77 can be used to compare diverse, nonpeptidic substrates containing a coumarin fluorophore, against a protease of interest. The advantage of this method is that scaffolds with poor binding affinity will not be overlooked, as turnover of these substrates results in accumulation of a fluorescent signal over time. Hits are then converted into potent Global profiling of all reactive cysteines in a proteome; iodoacetamide-based reporter molecules will react primarily with the more reactive cysteines. Using isotopically labeled reporter molecules, this method can be used to predict functional cysteines in proteomes as well as to identify targets. When the methods described here are used to evaluate the specificity profile of a reversible inhibitor, the labeling conditions should be adjusted so that the covalent probe does not outcompete the inhibitor. Because these methods have a good dynamic range, this can be accomplished by lowering the probe concentration or decreasing the labeling times.
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Global profiling of compound specificity. Although selective ABPs are very useful tools to study the biology of a specific target, broad-spectrum ABPs are valuable for globally profiling the effect of an inhibitor against all members of a protease family (Fig. 4c,d ) 80 . This type of assay can provide information regarding the partitioning of the drug within specific tissues, as it can be done in vivo by pretreating an entire animal with an inhibitor and then labeling residual activity with an ABP directly in vivo or in tissue extracts 30, 81, 82 .
In one application of this method, a cell-permeable broad-spectrum proteasome probe showed that the clinical proteasome inhibitor bortezomib (Velcade)-currently used for the treatment of multiple myeloma-targets unexpected proteasomal subunits 83 . In a second application of this method, another broad-spectrum ABP identified several serine proteases as additional off-target proteases 84 .
In an ABP-based structure-activity relationship study, cathepsin K inhibitors that failed in phase II clinical development for the treatment of osteoporosis 85 were shown to accumulate in lysosomes in vivo, inhibiting off-target cathepsins and leading to an accumulation of intracellular collagen 23, 86 . This lysosomotropism is presumably due to the presence of a basic amine group that becomes charged in the acidic lysosomes. A new inhibitor, odanacatib, that lacks a basic amine did not have this effect, allowing it to enter phase III clinical trials. Thus, these kinds of assays can potentially explain some of the side effects of such drugs and inform future inhibitor development. All the ABPs mentioned above contain an electrophilic reactive group that irreversibly modifies the cysteine, serine or threonine catalytic residues of target proteases. However, this strategy is not applicable to aspartate and metal proteases because hydrolysis of the peptide bond is mediated by a water molecule. Nonetheless, metalloprotease ABPs that can be used to pull down proteases for MS identification and quantification 87 or for in vivo imaging applications 44 have been designed by incorporating a moiety that coordinates the metal ion inside the active site. Another approach is to introduce a photo-cross-linking group in addition to the chelating moiety to achieve covalent modification of metalloproteases [88] [89] [90] . Specific probes using these design principles have been used to study the biological function of aminopeptidases in P. falciparum 89 , and broadspectrum probes have been used to select HTS hits based on their specificity profile 91 , or to identify active metalloproteases in tissue extracts 88 . The photo-cross-linking approach has also been used to target the presenilin aspartate proteases involved in the processing of amyloid proteins 92 .
Although ABPs are valuable to assess target selectivity, this method depends on having probes that can broadly target all the members of a protease family. Recently, a method was developed for globally profiling the reactivity of all cysteines in a proteome by using an isotopically labeled probe containing iodoacetamide as a general alkylating agent 93 (Fig. 4d) . Because cysteine proteases contain a highly reactive cysteine, this method could be used to monitor the effects of a given compound on the entire protease class. This method should also, in principle, be applicable to studying serine protease by using a general serine reactive reporter.
In summary, by carrying out HTS in intact cells, it is possible to select for compounds that are cell permeable and able to inhibit the target in its biological context. The specificity of these compounds can then be quickly evaluated using an activity-based global profiling method, which also provides the SAR information necessary to design more specific inhibitors. The validity of this approach was recently demonstrated with the identification of triazole ureas as potent serine hydrolase inhibitors that were then developed into highly selective inhibitors in vivo 32 .
Concluding remarks
In summary, we feel that the main challenges facing protease drug development is a lack of understanding of the complex mechanisms by which protease activities are regulated and of the multiple functions they have in diverse biological pathways. In addition, one of the main hurdles to developing safe protease inhibitor drugs and understanding the biological function of proteases is the difficulty in developing specific inhibitors in vivo. Although the classical techniques for development of inhibitors in vitro yield potent inhibitors, these compounds often do not translate into specific and/or effective inhibitors in vivo, owing to stability, cell permeability or partitioning issues. Screening compounds in intact cells and animal models at an earlier stage in the drug-development process should help overcome some of these challenges. This would allow researchers to focus hit-to-lead optimization on those compounds that are able to reach their target within a biologically relevant context. Activity-based protein profiling methods could then be used to determine the specificity of lead inhibitors against all members of a protease family and thus facilitate the design of highly specific inhibitors with reduced off-target effects.
ABPs are valuable imaging agents that can report on protease activity at the protein, cellular and whole-organism levels. They are therefore ideal tools not only to study the biological function of proteases but also to assess the in vivo efficacy of protease inhibitor treatments in real time. Moreover, identification of natural substrates using new proteomic methods will help define how proteases perform specific biological functions and provide biomarkers to evaluate whether inhibition of a protease target results in downstream biological effects. Overall, we believe that the advent of new tools such as ABPs, global protein profiling and new proteomic approaches will allow the focus of protease inhibitor development to shift from potency in vitro to specificity and efficacy in vivo.
Note: Supplementary information is available on the Nature Structural & Molecular Biology website.
